Rapid recurrence of cancer after treatment with oncogenic K-RAS-specific inhibitors suggests that early tumor lesions are resistant to oncoprotein inhibitors, and that secondary oncogene activation and resistance to the effect of the inhibitors leads to the resumption of cell proliferation [34]. Here, KRAS is linked to cancer.